RNAC
Cartesian Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$6.08
−3.03%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$6.39
From 52W high−42.59%
Volume201517.00
Market cap$183.95M
P/E (TTM)—
P/S (TTM)124.5x
Div yield—
Key dataOct 19, 2026
Open
$6.39
From 52W high
−42.59%
Volume
201517.00
Market cap
$183.95M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
27.5
MomentumView details →
1D Return
−3.03%
YTD Return
−15.53%
SummaryUpdated Jun 1, 2026
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) is a clinical-stage biopharmaceutical company that was incorporated in 2007 and is headquartered in Watertown, Massachusetts. The company operates under the business name Selecta Biosciences and focuses on developing innovative nanoparticle-based immunomodulatory drugs for treating and preventing human diseases. Originally founded as a biotechnology research company, Cartesian has evolved into a clinical-stage enterprise with multiple therapeutic programs spanning gene therapy, biologics, and autoimmune treatments, with several candidates advancing through various phases of clinical trials.
Similar companies
Latest newsMore news →
Cartesian Therapeutics granted stock options to purchase an aggregate of 121,900 shares at $7.22 to four new employees as employment inducement awards on October 1, 2026.18d agoCartesian Therapeutics announced additional retreatment data for its Descartes-08 therapy showing deep and durable responses in patients with myasthenia gravis.21d ago